Business Wire3h
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patient…
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
The American Journal of Managed Care4d
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Zacks Investment Research on MSN4d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Medscape21d
Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
Medscape10d
1 in 5 Patients Experience Skin Toxicity With Nivolumab/Relatlimab
In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...
Cure Today25d
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...
Cancer Research UK4y
A trial of SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma (The Scope Study)
A doctor or nurse gives the injections using a special needle free device. The SCIB1 or iSCIB+ enters the skin at high pressure and reaches the muscle. The team can tell you more about this. You have ...